Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Potassium voltage-gated channel modifier subfamily G member 4 (KCNG4) is a regulatory subunit of the voltage-gated potassium (Kv) channels, specifically associated with the modulation of heterotetrameric channel complexes such as those formed with KCNB1 (Kv2.1). KCNG4 does not form functional channels on its own but alters channel properties—such as activation kinetics and voltage dependence—when coexpressed with pore-forming Kv alpha subunits. It is primarily expressed in the brain and is associated with physiological processes like neuronal excitability, neurotransmitter release, and other potassium channel-related activities. Mutations or dysregulation in KCNG4 have been implicated in congenital stationary night blindness and distal arthrogryposis. No direct KDNG4-selective drugs are known, and its therapeutic relevance is primarily as a modulator of complex channel assemblies rather than as an independent drug target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Potassium voltage-gated channel modifier subfamily G member 4 (KCNG4).